Current Clinical and Medical Education

Received 25 May 2024 | Revised 28 May 2024 | Accepted 25 Jun 2024 | Published Online 1 Jul 2024

Published By: Vision Publisher

ISSN 2942-0792

CCME 02 (7), 01-11

Original Article

Applications of Bone Marrow and Blood Stem Cell Transplantation, Evaluation of Stem Cell Donors, and Administration of Blood Products

Hassan Nizar Jabbar Saleh Al-Shuwaili[1], Mohammed Shamil Kamel Al-Jubouri[2], Mortadha Muhammad Kayuf Hatem Al-Kuwaishi[3], Hind Riyad Hussein Ahmed Al-Alloush[4]

[1,3] Wasit University, College of Science - Department of Biology, Iraq

[2]Anbar University, College of Science - Department of Biology, Iraq

[4]University of Babylon, College of Science for Women, Department of Biology, Iraq

Abstracts: The umbrella word "stem cell transplantation" describes a variety of procedures. Hemopoietic stem cells are obtained for allogeneic transplants from a healthy, HLA-matched donor—a relative or a stranger—either from the patient's peripheral blood, bone marrow, or umbilical cord blood. Patients' own peripheral blood or bone marrow are used to harvest stem cells for autologous transplants. The current gold standard for stem cell transplantation is autologous transplantation, in which the patient serves as the donor. Thanks to advancements in cryopreservation, patients can now securely retain their bone marrow indefinitely during conditioning chemotherapy without worrying about the catastrophic loss of stem cells that occurs upon thawing. Patients experienced protracted neutropenia and thrombocytopenia, and the recovery of peripheral blood cell counts following transplantation of cryopreserved marrow that had been subjected to chemotherapy was sluggish. The process was less risky than allogeneic transplants, and neither graft-versus-host disease nor protracted immunosuppression occurred. Early research in the 1980s found that peripheral blood marrow stem cells circulated in low amounts in healthy individuals but in high numbers in patients regaining their neutropenia after chemotherapy. Granulocyte colonystimulating factor and other bone marrow growth factors improved stem cell outputs even further when administered to patients while they were recuperating. After receiving only the growth factor, few patients had an abnormally high amount of stem cells. This method typically allows for a safe autologous transplant by harvesting enough cells from the peripheral blood over the course of two or three days. Compared to patients who received autologous bone marrow that had been cryopreserved, those who underwent this sort of transplant had a quicker recovery of peripheral blood cell counts. Nowadays, adults undergoing stem cell transplants are most commonly drawn from peripheral blood.

Keywords: Bone Marrow, Blood Stem Cell Transplantation, Stem Cell Donors, Administration

Corresponding Author: Hassan Nizar Jabbar Saleh Al-Shuwaili†, Wasit University, College of Science - Department of Biology, Iraq

Supplementary information The online version of this article (https://doi.org/xx.xxx/xxx.xx) contains supplementary material,which is available to autho-rized users.

Introduction:

Not only do hematopoietic stem cells recapitulate themselves, but they also give rise to every lineage of blood cells. Theoretically, these events take place as a result of asymmetric cell division, in which one daughter cell becomes an exact copy of the parent cell while the other dedicates itself to further differentiation into fully formed red blood cells. Rarely do we find true hematopoietic stem cells in bone marrow, and even less often do we know what mechanisms control their proliferation and differentiation. so is not easy to identify stem cells; the best way to do so is to look for the CD34 antigen, which is expressed by these cells, and to look for the absence of any protein that is found on cells that have committed to developing into a certain cell lineage. Even though CD34 is expressed by all stem cells, pluripotent stem cells comprise just a small percentage of the CD34+ cells. A large percentage of CD34 + cells are committed lineage progenitors [1-3]. Following myeloablative treatment, hematopoietic progenitor cells are infused into the recipient's bone marrow in sufficient quantities to engraft it. This procedure is known as stem cell transplantation. Stem cells can come from a variety of sources, including the donor, the receiver, an identical twin, a close sibling, or even someone completely unrelated. Bone marrow, peripheral blood, or blood from the umbilical cord are all potential sources for the stem cells. These days, peripheral blood is the go-to source for autologous stem cells, while bone marrow is the go-to for allogeneic, or unrelated, stem cells. Stem cell harvesting from all donors' blood is becoming more popular. In cases where conventional dose chemotherapy is ineffective, hematologic malignancies, solid tumours, congenital immunodeficiency disorder, and bone marrow failure all warrant stem cell transplantation. Only individuals with a favourable risk-benefit ratio should undergo stem cell transplantation, due to the high potential for harm. Patients are considered to be in excellent health if their heart, lungs, kidneys, and liver all operate well and if their overall performance status is satisfactory. Patients who are currently experiencing an infection should, if at all feasible, postpone stem cell transplantation. Stem cell transplantation offers a better chance of helping cancer patients whose disease has gone into remission or who have shown improvement after standard treatment [4, 5]. Age of the recipient, stem cell source, donor-recipient HLA type, disease kind, and disease stage are among the several variables that affect the success of stem cell transplantation. Each disease segment goes into detail regarding the indications for and outcomes of stem cell transplants.



Figure 1. Basic principles of stem cell transplantation

Source Selection for Stem Cells

The availability of stem cell donors, the recipient's age, the kind of disease and its remission status, and other factors are considered when deciding where to get stem cells for a transplant. Using either autologous or allogeneic stem cells comes with its own set of advantages and disadvantages. Despite the advantages of using disease-free allogeneic stem cells, there remains a danger of graft-versus-host disease (GVHD), a potentially fatal consequence [6, 7]. GVHD happens when the skin, liver, and/or gastrointestinal tract are injured due to the immune response that the stem cell graft's T cells start, which is against host antigens. Allogeneic stem cell transplantation is usually reserved for younger patients due to the fact that the risk of GVHD rises steadily with age.

Source Selection for Stem Cells

The graft-versus-leukemia (GVL) effect is the name given to this phenomena because it is most commonly seen in individuals with myeloid leukaemia, particularly chronic myelogenous leukaemia. The risk of extra early mortality from acute GVHD may outweigh, or be less than, the benefit of the GVL effect when allogeneic stern cells are utilised. This risk varies by patient age, disease, and remission status. Thus, the anticipated risk of acute GVHD versus the possible benefit of a graft-versus-malignancy effect is a factor in the choice of allogeneic versus autologous stern cells for transplantation in any given patient. Furthermore, when autologous stern cells are not sufficiently tumour free, allogeneic stern cells must be employed for hereditary illnesses, immunodeficiency states, aplastic anaemia, and malignant disorders [8, 9]. When a related donor is unavailable and allogeneic transplantation is the preferred option, a stern cell donor who is HLA-matched but unrelated can be utilised. Receiving bone marrow from an unrelated donor increases the recipient's risk of GVHD compared to using a related donor. There are greater immediate problems with transplants from matched but unrelated donors (particularly graft against host reactions), but the long-term outcomes seem to be similar to those from matched family donors. A large number of hematopoietic stern cells are present in the umbilical cord blood that is collected at childbirth. The overall number of cells that may be retrieved is minimal, and the stern cells found in umbilical cord blood (UeB) are more primitive compared to those found in bone marrow and peripheral blood. This causes a postponement of engraftment after UCB cell transplantation. There is currently no consensus on the minimal quantity of UCB stern cells needed to achieve stable engraftment. The graft's T cells are relatively innocent, which is a possible benefit of UCB. Because of this, UCB stern cells can be used in patients with a higher level of HLA discrepancy than can be tolerated when bone marrow or peripheral blood are used as stern cell sources, and the risk of GVHD is reduced. Patients who need an allogeneic bone marrow transplant (BMT) but cannot find a compatible relative or stranger can benefit most from UBC stern cells at this time. Most cord blood transplants have been performed on children up till now because there is a scarcity of adult stem cells in cord blood.

TRANSPLANTATION USING AUTOLOGOUS STEM CELLS

Several cancers have autologous stern cell transplantation as a confirmed therapy option when allogeneic donors are unavailable or graft-versus-malignancy effects fail to provide desired results. Certain solid tumours, acute myelogenous leukaemias, certain instances of chronic myelogenous leukaemia, recurrent non-Hodgkin's lymphomas, and Hodgkin's disease are all examples of conditions that can be treated with autologous transplantation. For these indications, it was demonstrated that regular chemotherapy is less efficacious than high-dose chemotherapy with bone marrow reinfusion. In a practical sense, after chemotherapy and mobilisation, the autologous marrow or peripheral stem cells are collected and preserved in liquid nitrogen. Similar to allogeneic transplantation, autologous transplantation is done following further chemotherapy or conditioning [10]. Patients with a modest tumour load or tumours that respond to chemotherapy tend to have the greatest outcomes from autologous transplantation. While gene-marking studies have demonstrated that autologous transplantation can avoid the toxicities of allogeneic transplantation, such as graft-versus-host reactions, there is a danger of reinfusing a certain number of tumour cells. Despite their theoretical appeal, purging procedures—which include tumour cell removal and positive selection for CD34+ cells—often lead to the loss of some healthy progenitor cells .

How to Choose and Assess a Stem Cell Donor

Stem cell donors are chosen based on how well their tissue types match those of the recipients. To check this, we use peripheral blood leukocytes for HLA serologic testing. It is common practice to use antisera against the HLA A, B, and DR loci to ascertain whether two related individuals are HLA compatible. There are a total of six antigens tested for because every person possesses two alleles at each HLA locus. There is a 1/4 chance that the patient's sibling(s) will have the same HLA gene. They are more likely to share a haplotype with the patient unless the parents are blood relatives. The primary utility of serologic testing in the evaluation of unrelated donors is as a screening tool. Unfortunately, serologic test antibodies are not excellent HLA antigen discriminators. Even when serologic testing reveals that two HLA antigens are identical, there may be subtle variations in the amino acid sequence. So, once initial serologic screening reveals that a possible unrelated stem cell donor is HLA compatible with the patient, molecular DNA studies [12, 13], such as polymerase chain reaction (PCR), are being employed more and more to assess their suitability. Although class I HLA allele testing is gaining popularity, polymerase chain reaction (PCR) analysis of the HLA DRBI gene is now the most used molecular test. After finding a suitable donor, the next step is to check for any

health issues that would prohibit the donation of stem cells using a combination of a physical and laboratory evaluation. Hepatitis viruses, human T-cell leukaemia virus type I or type 2, and the human immunodeficiency virus are all ruled out through laboratory testing. Donors of bone marrow typically provide 1-2 units of blood before the procedure, with the exact amount dependent on the amount of marrow that will be harvested. This allows for reinfusion after the harvest, in the event that symptomatic anaemia is necessary.

Collecting Stem Cells

The bone marrow is the typical location for hemotopoietic stem cells. This means that stem cell transplantation from bone marrow is a safe and effective option. In the operating room, the bone marrow donor is placed in the prone position after receiving spinal, epidural, or general anaesthesia. Sterile drapes are used to cover the skin around the iliac crests after it has been washed with betadine and iodophor. The process of retrieving bone marrow involves introducing a trocar into the iliac crest marrow space multiple times, drawing out three to five millilitres of bone marrow into a syringe that has been heparinized, withdrawing the trocar, and then ejecting the marrow into a bag that has been filled with heparinized medium [14]. It is common practice to conduct a cell count around halfway through the procedure to ensure that the collection is adequate. When the volume objective, which is determined from the midcount, is attained, the bone marrow collection process stops. The next step, after collection, is to filter the bone marrow to remove any clots or shards of bone.

Although stem cells are not common in peripheral blood, they can be stimulated to enter the circulation after chemo or when hematopoietic growth agents are administered. For normal donors, stem cell mobilisation is often done by injecting 10 /lg/kg of granulocyte colony-stimulating factor (G-CSF) subcutaneously once day until the collection is finished. You can also mobilise peripheral blood stem cells (PBSCs) with granulocyte macrophage colony-stimulating factor (GM-CSF). Recent research has demonstrated that mobilising PBSCs using stem cell factor in addition to G-CSF is more effective than with G-CSF alone. It is possible to mobilise peripheral blood stem cells (PBSCs) while the neutrophil count recovers in cancer patients by administering growth factors daily starting on the day after chemotherapy is finished. When using hematopoietic growth factors alone, stem cell harvest typically starts 5 days after treatment begins. Collections can be started in patients who have had their stem cells mobilised with growth factors after chemotherapy as soon as the CD34+ cell count in their peripheral blood exceeds the level set by each facility. Immature hematopoietic progenitor cells, such as pluripotent stem cells, express the CD34 antigen. Apheresis is the process of stem cell harvesting. It involves a machine continuously drawing blood from the donor's vein, centrifuging it to extract the mononuclear cell fraction, and then returning the rest of the blood through another vein. As part of this process, sodium citrate is used to anticoagulate the blood. This method often yields a cell product that is mostly composed of immature granulocytes, lymphocytes, and monocytes, as well as immature hematopoietic progenitor cells, which often include stem cells.

Rehabilitative Treatment

There are two possible uses for the conditioning therapy that is given before stem cell transplantation. One is to minimise the tumour burden in patients with cancer. The other is to suppress the host immune system so that engraftment can take place in patients receiving stem cells from related or unrelated donors. Radiation and chemotherapy, or chemotherapy alone, can be used as conditioning therapy. Patients with cancer are often treated with chemotherapeutic drugs that are particular to their disease. The medications are chosen in a way that prevents the cancer from developing a resistance to those that were employed earlier in the therapy process. To further reduce the risk of harm to organs other than the bone marrow, the conditioning treatments are selected such that their main toxicities are hematologic and their nonhematologic toxicities do not overlap. A new strategy for stem cell transplantation has been studied recently: nonmyeloablative conditioning regimens utilising immunosuppressive chemotherapies such fludarabine and cyclophosphamide. To enable engraftment of the donor immune system, the nonmyeloablative method employs minimally toxic chemotherapeutic dosages, as the GVL effect is essential to the treatment of various cancers after allogeneic BMT. It is believed that the recipient's malignant nancy can be eradicated by the transplant immune system. We don't know enough about this method to draw any conclusions about which patients would benefit from this less harsh conditioning treatment just yet.

Administration of Blood Products

Transfusing blood products into stem cell transplant recipients requires special care, such as irradiating all blood products before transfusion, only giving seronegative allogeneic transplant recipients cytomegalovirus (CMV)-negative blood products, and avoiding allergen sensitization. Pancytopenia occurs in patients undergoing stem cell transplants after conditioning therapy but before bone marrow recovers. In order to avoid potentially fatal thrombocytopenia and clinical anaemia, transfusion support is necessary throughout this time. Transfusions of packed red blood cells are usually administered as a preventative measure when haemoglobin levels drop below 9 g/dL. Platelet transfusions are administered to stable patients when their platelet count falls below lO,OOO/)lL, and to febrile patients when it falls below 20,OOO/)lL. In order to avoid transfusion-related GVHD, platelet transfusions are necessary because a high platelet count stops the product's lymphocytes from multiplying in reaction to host antigens. In allogeneic transplant recipients, CMV can cause potentially fatal pneumonia, hepatitis, or colitis. Only blood products from donors who have tested negative for CMV should be given to patients who have not been exposed to the virus. There is evidence that filtration of blood products reduces the risk of CMV transmission by reducing leukocytes [15, 16]. It is debatable whether CMV-negative blood products may be substituted with leukocyte-reduced ones. In order to keep patients from becoming resistant to platelet transfusions and to lower the risk of graft rejection in allogeneic transplants, it is important to prevent alllosensitization, or the development of immunity to HLA. Due to the fact that HLA antigens are expressed on platelets, it might be challenging to maintain sufficient platelet levels after a transplant if the recipient develops humoral or cellular immunity against a broad diversity of HLA. The danger of allosensitization can be reduced by reducing the number of white blood cells in blood products. As a result, leukocyte-reduced blood products should be administered to all stem cell transplant recipients. Also, instead of combining platelet products from multiple donors, it is preferable to get them from a single donor using apheresis. HLA-matched platelet transfusions may be necessary for patients who are unable to receive platelets through other means. Patients undergoing less rigorous conditioning regimens for nonmalignant illnesses are at increased risk of graft rejection due to allosensitization, which happens before transplant conditioning. To reduce the likelihood of graft rejection, individuals planning to undergo allogeneic stem cell transplantation should never get transfusions of blood products from relatives or close friends before the procedure. Patients with aplastic anaemia usually get moderate conditioning therapy before transplantation, but it is important to minimise the number of blood product infusions given to them .

Treatment and Prevention of Infections Occurring After a Transplant

Myeloablative therapy causes significant neutropenia, which puts transplant recipients at risk for developing fungal or bacterial infections. (In this context, a neutropenia is defined as a white blood cell count below 500/(lL)). Historically, prophylactic "gut sterilisers" have been used to try to decrease the problem of infections during the neutropenic phase, which often start in the gastrointestinal system. Numerous facilities still rely on poorly absorbed antibiotics like norfloxacin (400 mg orally twice day), oral antifungal drugs like nystatin (1 million units orally four times day), and clotrimazole (10 mg troche dissolved in the mouth four times day), despite the lack of conclusive evidence that these treatments effectively decrease infections. Rapid and empirical treatment is required for the initial neutropenic fever that develops in transplant patients. Administer intravenous antibiotics with activity against a broad spectrum of gram-negative bacilli, gram-positive cocci, and anaerobic organisms as soon as feasible when appropriate cultures are collected in the absence of an identifiable source .

If cultures reveal the cause of the infection, antimicrobial treatment can be adjusted accordingly. It is possible to start empiric antifungal treatment if fevers continue after antibiotics and no obvious cause has been found, particularly if a long duration of neutropenia is expected. While amphotericin B at a dose of 0.5 mg/kg/d has been standard practice in this context, early results from studies with azole antifungal drugs indicate that they may be just as effective—if not more so—with far less side effects. In cases when a fungal infection has been confirmed, a full dose of amphotericin B (1 mg/kg/d) is necessary. When administered empirically, antimicrobial therapy can typically be discontinued as neutropenia resolves (absolute neutrophil count >500/~). However, in the event that the source of infection is determined, a complete course of treatment is necessary. A big issue after allogeneic bone marrow transplantation was pneumocystis pneumonia before routine preventative measures were used. These days, patients take 160 mg of trimethoprim and 800 mg of sulfamethoxazole (TMP/SMX) three times a day for around seven days before transplantation, with a two-day break before stem cell infusion. After the bone marrow transplant, the patient will take

TMP/SMX three times a day with 5 mg of leukovorin twice a week [17, 18]. The prophylactic use of pneumocystis medication is maintained until the patient stops taking any immunosuppressive medication. Patients who are allergic to sulfa can take 300 mg of aerosolized pentamidine once a month instead of TMP/SMX .

After receiving an allogeneic bone marrow transplant, patients who test positive for CMV run the danger of contracting hepatitis, colitis, or a potentially deadly form of pneumonia due to the virus's reactivation. Cases of cytomegalovirus infection have dropped dramatically due to preventative treatment. Weekly intravenous immunoglobulin at a dose of 0.5 g/kg is administered to all patients until 100 days after transplantation. For about a week before transplantation, patients who test positive for CMV take gancyclovir at a dose of 5 mg/kg/day; they cease taking it two days before stem cell infusion. Starting on the 5 days after the last TMP/SMX dosage, gancyclovir is given at a dose of 6 mg/kg/d until 100 days after the transplant, or until the neutrophil count reaches 1000/1 litre. Because gancyclovir is myelosuppressive, it is important to monitor blood counts so that if neutropenia develops, medication therapy can be reduced or temporarily stopped. Oral administration of acyclovir is only possible once the lesions have crusted over, which means that the dosage must be adjusted for renal insufficiency (creatinine clearance). In cases of disseminated zoster, intravenous treatment must be continued for a longer period of time .

Failure in Grass

When severely hypocellular bone marrow and pancytopenia continue for more than 21 or 28 days after a bone marrow or peripheral blood stem cell transplant, respectively, it is referred to as graft failure. Inadequate stem cell administration, graft quality as a result of the patient's extensive history of treatment with alkylating agents, or extensive manipulation of the graft (such as treating it with cytotoxic agents to purge tumour cells) are all factors that increase the likelihood of graft failure in patients receiving autografts. There are several factors that can increase the likelihood of graft failure in patients receiving allografts. These include a history of severe allergic reactions to blood products, insufficient conditioning therapy to eliminate the recipient immune system, HLA incompatibility with the donor, a lack of T lymphocytes in the graft, and an inadequate dose of stem cells. Any transplant patient runs the risk of adverse effects from myelosuppressive medicine administration. Another possible cause of chronic pancytopenia after a bone marrow transplant is a persistent or recurrent cancer of the bone marrow. When allogeneic transplantation is being considered, a bone marrow biopsy can also be done to detect donor cells using restriction fragment length polymorphism (RFLP) analysis, which helps confirm graft failure. In cases where a chromosomal aberration is known to have occurred during the patient's cancer treatment, cytogenetic analysis of the bone marrow is conducted. Myeloid growth factors and transfusion support are common components of treatment. G-CSF, administered at doses of 5-10 flg/kg/d or GM-CSF, administered at a dose of 250 flg/m2/d, can be utilised in this context. Patients experiencing graft failure after receiving an allotransplant should also make every attempt to collect more stem cells from the donor. These patients typically get additional immunosuppressive medication before receiving a second stem cell infusion in order to reduce the likelihood of graft rejection.

GVHD

Inherited GVHD can occur in patients who receive stem cells from a donor who is not related to them. The recipient's advanced age, an HLA mismatch, an unrelated donor, a parous female donor, and an increase in the number of T cells in the graft are all factors that can raise the risk of this problem. The GVHD condition is often separated into two phases: the acute phase, which happens within the first hundred days after transplant, and the chronic phase, which follows. The skin, intestines, and liver are all potential sites of involvement in this illness. Palmar, plantar, and auricular erythema are the most common skin involvement symptoms, and they typically appear first. A generalised erythematous maculo papular rash can develop from acute GVHD of the skin. Bullae and desquamation appear on severely affected skin. The first sign of acute liver involvement is a small increase in blood transaminase and alkaline phosphatase levels, along with an asymptomatic rise in conjugated bilirubin level. Although the liver's synthetic activity is initially maintained, hepatic encephalopathy and liver failure can develop in cases of severe illness. The most noticeable symptom of gastrointestinal GVHD is diarrhoea, which can sometimes become very watery. Colonic mucosal shedding, haemorrhage, ileus (bowel distention), and possible perforation are symptoms of severe enteric involvement. Gastritis, esophagitis, or oral mucositis are the most common manifestations of a disease that primarily affects the upper gastrointestinal system. Symptoms such as nausea, vomiting, and prolonged anorexia may be experienced by patients. Past acute GVHD, recipient age, using an unrelated or mismatched donor, and infusing a

large number of T lymphocytes with the graft are all factors that increase the risk of complications. The involvement of the skin is marked by lichenified plaques or an easily ulcerating thin epidermis. The dermis hardens and joint contractures can form during contrast. Vitiligo is less common but can occur alongside hyperpigmentation. Damage to the skin can lead to the loss of hair, sweat glands, and nails. Xerostomia can lead to difficulty swallowing, whereas xerophthalmia makes the eyes seem gritty. Oral mucositis, esophageal webs, and malabsorption are symptoms of chronic GVHD in the GI tract. It is possible for the buccal mucosa to display white plaques or reticulations. In cases of chronic hepatic GHVD, the most aberrant test value is usually the alkaline phosphatase, while the tras.

GVHD

There is less abnormality with saminases and bilirubin. Bronchiolitis obliterans is a symptom that might appear when the lungs are involved. Chronic GVHD patients are more likely to contract opportunistic infections due to inadequate immunologic reconstitution. Although acute cutaneous GVHD is typically diagnosed clinically, the best way to confirm involvement in the liver or gut is with a biopsy. This is due to the fact that other posttransplant problems, particularly infections, might present similarly. The skin's histopathology shows lymphocytic infiltration into the epidermis and perivascular area, as well as vacuolization of the dermal-epidermal junction [19]. The breakdown of the epithelial cells lining the interlobular bile ducts and portal lymphocytic infiltration are signs of liver involvement. One hallmark of crypt cell vacuolation ("exploding crypt cells") is its appearance in colonoscopy and rectal biopsies. The majority of patients are prescribed cyclosporine doses that will keep their serum concentrations between 150 and 200 ng/mL when tested with a monoclonal antibody assay or 200-400 ng/mL when tested with a polyclonal anti body assay, in order to avoid acute GVHD. This can be accomplished by starting with an intravenous loading dosage of 3 mg/kg the day before transplantation and gradually increasing it to 2-3 mg/kg/d through continuous intravenous infusion. Once the patient is able to swallow, the intravenous cyclosporine dose is administered orally twice day for a minimum of six months, following which it is progressively reduced. It is important to regularly monitor blood levels of cyclosporine as well as renal and hepatic function in order to prevent medication toxicity. Inhibiting interleukin 2 synthesis is how cyclosporine suppresses T-lymphocyte activation. Patients older than 40 years old, adults with chronic myelogenous leukaemia, and those getting grafts from unrelated donors are common recipients of methotrexate. One typical regimen is to give the patient 15 mg/m2 on the first day after the transplant, followed by 10 mg/m2 on the third and sixth days. One way methotrexate works is by eliminating the growing number of alloreactive T cells in the graft. In addition to reducing the likelihood of GVHD, intravenous immunoglobulin is utilised to forestall CMV infection. Up until 100 days after the transplant, it is typically administered weekly at a dosage of 0.5 g/kg. Although high-risk patients may be given glucocorticoids to avoid GVHD, this does not increase survival rates. This survival benefit is countered by an increased risk of death from disease relapse due to a loss of the GVL effect and a higher rate of graft rejection, even while depleting T lymphocytes from the graft effectively decreases the risk of death due to acute GVHD. Research into whether or not reducing the likelihood of severe GVHD by depleting certain T-cell subsets can maintain the GVL effect is continuing. Glucocorticoid treatment is the mainstay of treating acute GVHD. Methylprednisolone or a comparable dose is initially administered intravenously at a rate of 1-2 mg/kg/d. Up to 1 g/d for 3 days of much higher methylprednisolone dosages may be given in cases of severe acute GVHD or lack of response. Due to the unreliability of oral administration, cyclosporine should only be administered intravenously when gut GVHD is present. A randomised controlled trial has not yet examined the effect of antithymocyte globulin (15-20 mg/kg/d for 4-5 days) on outcome in patients with severe acute GVHD. After ruling out gastrointestinal infections, parasites, or Clostridium difficile as possible causes of acute diarrhoea, symptomatic treatment can be started. For subsequent episodes of diarrhoea, opium tincture is often helpful in lowering the volume. The somatostatin analogue octreotide acetate is administered intravenously starting at 200 ~g/d. given in divided doses, could be beneficial for certain individuals. The treatment of GVHD affecting the liver may benefit from ursodeoxycholic acid 10-15 mg/kg/d, according to limited clinical data. Topical steroids can be used to treat isolated cases of severe GVHD on the skin. Medications that inhibit the immune system tend to have less of an effect on chronic GVHD compared to the acute form. Glucocorticoids are the initial treatment options for chronic GVHD, just as they are for acute GVHD. There have been a lot of different treatments attempted, but nothing has worked reliably. Some people may benefit from the antimycobacterial medication clofazimine (300 mg orally daily) or thalidomide (200 mg orally four times daily), according to unproven studies.

PEUMoNIA AFTER TRANSPLANT

Patients undergoing stem cell transplantation, particularly those receiving allogeneic or unrelated stem cells, are at high risk of contracting pneumonia due to the severe immunosuppression they experience. Immunocompetent people often have mild or self-limiting illness caused by many of these pathogens. Inadequate treatment can lead to fast illness progression, and there are a lot of possible infections to consider while choosing an empiric medication. Consequently, in the treatment of pneumonia following a transplant, it is frequently essential to establish a clear etio logic diagnosis. Depending on the clinical situation, one should approach a patient with posttransplant pneumonia differently. After getting the right sputum and blood cultures, patients with localised pneumonia who were already taking antibiotics can be effectively treated with empiric broad-spectrum antibiotics (refer to Table 4.3). If a patient develops diffuse or interstitial pneumonia, or if they have pneumonia while taking broad-spectrum antibiotics, bronchoscopy should be considered. A transbronchial biopsy and bronchoalveolar lavage are necessary procedures to carry out. Appropriate diagnostic examinations should be conducted on specimens. Posttransplant pneumonia can be caused by a broad range of microorganisms, including bacteria, fungi, and viruses. Posttransplant pulmonary infiltrates can have a variety of causes, including radiation or medication toxicity, recurring cancer, or other cancers. It may be prudent to treat patients empirically for all potential infectious organisms while you wait for test results. Without the right treatment, a patient's condition can quickly worsen. The antibiotic regimen can be streamlined after the diagnostic study results are in. Thoracoscopy or an open lung biopsy may be necessary if the results of the bronchoscopic investigations do not provide a diagnosis and the pneumonia does not improve with empirical treatment. Administering TMP/SMX intravenously at a dosage of 15-20 mg/kg/d is the standard treatment for Pneumocystis pneumonia. in three or four doses of TMP. Administer 4 mg/kg/d of pentamidine intravenously to patients who are allergic to sulfa medications. Allogeneic stem cell transplant recipients are required to take pneumonia prophylaxis, as previously mentioned. Patients who obtain the necessary prophylaxis are very unlikely to contract the infection. A 1 mg/kg/d intravenous dose of amphotericin B is necessary for the treatment of invasive fungal infections. adults and children, at a dosage of 2 mg/kg/day. A dosage of 1 g of amphotericin B is recommended for the treatment of Candida involvement in the pulmonary parenchyma, while 2 g of the drug is usually required for other fungal infections. Patients developing renal insufficiency should be considered for the use of liposomal amphotericin B. There is no evidence that azole antifungal medications are as effective as amphotericin B in treating invasive fungal infections in patients undergoing stem cell transplants. Subheading 4.9 explains how prophylactic gancyclovir can effectively prevent CMV pneumonia in individuals who have received an unrelated stem cell transplant or who test positive for the virus during an allogeneic transplant. Only CMV negative blood products should be administered to seronegative patients in order to protect them against infection. Autologous stem cell transplant recipients are very unlikely to get CMV pneumonia. The recommended course of treatment includes 20 days of 2.5 mg/kg gancyclovir every 8 hours and 10 doses of 0.5 g/kg intravenous immuno globulin. The recommended dosage of acyclovir for herpes simplex virus (HSV) or varicella zoster pneumonia is 10–12 mg/kg given every 8 hours. It is important to constantly monitor renal function and, in the event of renal insufficiency, reduce the dosage as needed. For stem cell transplant recipients, the most prevalent cause of pneumonia is adenovirus, influenza, parainfluenza, or respiratory syncytial virus (RSV). So, people receiving stem cell transplants shouldn't have any close relatives or coworkers who are sick with a virus in the room with them. Once pneumonia has been diagnosed, no medication seems to work against these infections. There has been a lack of sufficient research on the efficacy of preventive antiviral medication or surveillance cultures in trans plants. Aerosolized ribavirin 20 mg/mL given 18 hid with intravenous immunoglobulin 0.5 g/kg every other day effectively cured RSV infection of the upper respiratory tract that was diagnosed by surveillance culture. This regimen failed to effectively treat patients with established RSV pneumonia. Ribavirin is extremely difficult to safely give, irritates the skin, and can cause foetal harm. Consequently, hospitals should only administer aerosolized ribavirin if they have implemented sufficient safety measures to safeguard healthcare personnel from the drug's toxicity. The safety profile of ribavirin should be enhanced by a novel intravenous formulation. Glucocorticoids are usually effective in treating pneumonia caused by side effects of a treatment. When autologous stem cell transplantation causes diffuse alveolar haemorrhage, it is important to treat the patient quickly with glucocorticoids since the bleeding could be therapy-related. Careful exclusion of an infectious aetiology should precede treatment for each of these issues.

Hepatocellular Venous Impairment

The obstruction of hepatic venules causes hyper bilirubinemia, hepatomegaly, and ascites in hepatic veno-occlusive disease (VOD). Endothelial harm from radiation and/or chemotherapy used for conditioning is the culprit. One of the better known risk factors is a history of liver illness or hepatitis. Although there is no evidence that certain conditioning regimens increase the incidence of VOD, previous treatment with high-dose chemotherapy does put patients at elevated risk. It is necessary to have two of the following within 30 days of transplant to confirm the diagnosis of this disorder: jaundice (direct bilirubin >2 mg/dL), painful hepatomegaly, ascites, or an unexplained weight gain of around 5%. Regrettably, neither these criteria nor any clinical features of VOD allow it to be easily distinguished from other sources of posttransplant jaundice. Congestive heart failure, cholestasis (a condition caused by medicines or biliary tract disease), hepatitis (a condition caused by infection or drugs), and GVHD (a condition experienced by allogeneic transplant patients) are all possible explanations for V 0 D. One new indicator of veno-occlusive illness after stem cell transplantation is plasminogen activator inhibitor 1 (PAl-I). A examination of the patient's medications is part of the evaluation process for suspected VOD. The goal is to detect any medications that could cause cholestasis or hepatitis. The possibility of congestive heart failure is ruled out during the physical examination. Hepatitis serologies are tested by drawing blood when it is clinically warranted. To check the liver's vein flow and rule out biliary tree blockage, ultrasonography is employed. Excluding GVHD may necessitate a transjugular liver biopsy. Hepatic venule subintimal thickening due to reticulum or collagen lumenal obstruction, but thrombus-related histology is not present. Another possible complication of VOD is centrilobular hepatocyte necrosis. There is no definitive evidence that using heparin as a prophylactic measure against VOD reduces the incidence of this consequence. Additionally, it has been linked to

Infections of the Blood Vessels

substantial danger of haemorrhage. There is currently no treatment that has demonstrated a clear improvement in the outcome for people with established VOD. Although there have been reports of reversal of VOD in certain patients with recombinant human tissue plasminogen activator, no randomised clinical trials have been conducted. The management of fluid overload, coagulopathy, and encephalopathy, among other supportive care measures, continues to be the standard of therapy. It is possible that some patients with severe liver failure could be good candidates for an orthotopic liver transplant.

Surgical Microangioplasty

Both allogeneic and autologous gene stem cell transplants carry the risk of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, often known as thrombotic microangiopathy (TM). The toxicities of the conditioning programme and the immunosuppressive medicines given posttransplant are two potential contributors to the microvascular damage that underlies this illness. A increased risk may be conveyed by GVHD prevention using a combination of cyclosporine, methotrexate, and glucocorticoids, which is linked to the development of this illness. Between one and six months after a transplant, TM usually manifests as a gradual drop in haemoglobin and platelet counts. Additional symptoms such as neurologic issues, fever, or renal failure could be present. Similar to de novo TM, the diagnosis is made when you see fragmented erythrocytes on the peripheral smear, as well as intravascular hemolysis (higher reticulocyte count, serum lactate dehydrogenase, and indirect bilirubin levels; lower haptoglobin; positive urine hemosiderin). The presence of Escherichia coli strain 0157:H7 should be investigated in stool samples taken from individuals who exhibit symptoms of diarrhoea and TM. Some allogeneic transplant patients may find relief after discontinuing or significantly lowering their cyclosporine medication. Although some patients have found relief by therapeutic plasma exchange or filtering patient serum through a staphylococcal protein A column with an apheresis machine, these methods are usually not as effective as when utilised in the context of de novo TM.

CONCLUSIONS

Haematology is in for a thrilling next five to ten years. Patients without a compatible donor are currently among those who could benefit from allogeneic transplantation. This issue should be reduced if cord blood banks continue to grow, particularly if there are enough donations from minority groups to keep the banks running smoothly. If it is possible to successfully produce more stem cells from these tiny donors, the number of allogeneic transplants conducted could rise, and the number of people cured could fall as well. We also believe that other medical experts will need to work

together more closely in order to evaluate the role of autologous transplantation in treating additional solid tumours and autoimmune diseases that are currently untreatable.

REFERENCES

1. Forman SJ, Blume KG, Thomas ED, eds. Hematopoietic Cell Transplantation. 2nd Ed New York: Blackwell Science, 1999.
2. Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as a treatment for lymphoid malignancies. J Clin Oncol1998;16:2817-2824.
3. Rowe JM, Ciobanu N, Ascensao J, et al. Recommended guidelines for the manage ment of autologous and allogeneic bone marrow transplantation. Ann Intern Med 1994;120:143-158.
4. Rubinstein P, Carrier C, Scaradavou A, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 1998;339: 1565-1577.
5. Perry AR, Mackinnon S. Adoptive immunotherapy post bone-marrow transplantation. Blood Rev 1996;10:237-241.
6. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998;91:756-763.
7. Kolb HJ. Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation: EBMT Immunology and Chronic Leukemia Working Parties. Vox Sang 1998;74(suppl 2):321-329.
8. Ganser A, Karthaus M. Clinical use of hematopoietic growth factors. Curr Opin Oncol 1996;8:265-269.
9. Hebart H, Einsele H. Diagnosis and treatment of cytomegalovirus infection. Curr Opin Hematol 1998;5:483-487.
10. De Marie S. New developments in the diagnosis and management of invasive fungal infections. Haematologica 2000;85:88-93.
11. Lemoli RM, Curti A, Tura S. Negative selection of autologous peripheral blood stem cells. Baillieres Clin Haematol 1999;12:57-69.
12. Goldman JM, Schmitz N, Niethammer D, Gratwohl A. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe in 1998. Accreditation Sub-Committee of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998;21:1-7.
13. Burnett AK, Goldstone AH, Stevens RMF, et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial: UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet 1998;351:700-708.
14. Hortobagyi GN, Buzdar AU, Theriault RL, et al. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst 2000;92:225-233.
15. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: Intergroupe Francais du Myelome. N Engl J Med 1996;335:91-97.
16. Proctor SJ, Taylor PRA, Mackie M, Angus B, Jack F, White J on behalf of Scotland & Newcastle Lymphoma Group. A randomized controlled trial (SNLG HD III) of nonablative autotransplant versus further chemotherapy in patients with very poor risk Hodgkin's disease [Abstract]. Ann Oncol 1999;10(suppl 3):238.

17. Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med 1990;322:417-421.

18. McElwain TJ, Hedley DW, Gordon MY, Jarman M, Millar JL, Pritchard J. High dose melphalan and non-cryopreserved autologous bone marrow treatment of malignant melanoma and neuroblastoma. Exp Hematol 1979;7(suppl 5):360-371.

19. Laurence AD, Goldstone AH. High-dose therapy with hematopoietic transplantation for Hodgkin's lymphoma. Semin Hematol 1999;36:303-312.